Search

Author/Creator Laux, Douglas

1. 423 Safety and preliminary efficacy of intratumoral cavrotolimod (AST-008), a spherical nucleic acid TLR9 agonist, in combination with pembrolizumab in patients with advanced solid tumors. (10th December 2020)

Authors:
O'Day, Steven; Perez, Cesar; Wise-Draper, Trisha; Hanna, Glenn; Bhatia, Shailender; Kelly, Ciara; Medina, Theresa; Laux, Douglas; Daud, Adil; Chandra, Sunandana; Shaheen, Montaser; Gao, Ling; Burgess, Melissa; Hernandez-Aya, Leonel; Yeung, Cecilia; Smythe, Kimberly; DeGoma, Emil; Daniel, Weston; ...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A257
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Comparing high‐dose cisplatin with cisplatin‐based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC). (9th April 2019)

Authors:
Furqan, Muhammad; Snyders, Travis P.; Saqlain, Mohammed U.; Mott, Sarah L.; Laux, Douglas; Snow, Anthony; Anderson, Carryn M.; Watkins, John M.; Clamon, Gerald H.
Journal:
Cancer medicine
Issue:
Volume 8:Number 6(2019:Jun.)
Page Start:
2730
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma. Issue 1 (19th March 2019)

Authors:
Espinosa-Cotton, Madelyn; Rodman III, Samuel N.; Ross, Kathleen A.; Jensen, Isaac J.; Sangodeyi-Miller, Kenley; McLaren, Ayana J.; Dahl, Rachel A.; Gibson-Corley, Katherine N.; Koch, Adam T.; Fu, Yang-Xin; Badovinac, Vladimir P.; Laux, Douglas; Narasimhan, Balaji; Simons, Andrean L.
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 7:Issue 1(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Issue 10212 (23rd November 2019)

Authors:
Burtness, Barbara; Harrington, Kevin J; Greil, Richard; Soulières, Denis; Tahara, Makoto; de Castro, Gilberto; Psyrri, Amanda; Basté, Neus; Neupane, Prakash; Bratland, Åse; Fuereder, Thorsten; Hughes, Brett G M; Mesía, Ricard; Ngamphaiboon, Nuttapong; Rordorf, Tamara; Wan Ishak, Wan Zamaniah; Hon...
Journal:
Lancet
Issue:
Volume 394:Issue 10212(2019)
Page Start:
1915
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗